Immunoassay Developed for Quantitative Detection of Serum Interleukin‐6
By LabMedica International staff writers Posted on 07 Apr 2021 |

Image: The quantum dot (QD)‐based fluorescence lateral flow immunoassay (LFIA) strip can rapidly and accurately detect IL‐6 levels at different concentrations (Photo courtesy of University of South China)
Interleukin‐6 (IL‐6) is a multifunctional protein and is primarily produced by macrophages, monocytes, fibroblasts, and T lymphocytes, and plays important roles in immune regulation, hematopoiesis, inflammation, and tumorigenesis.
IL‐6 has shown the highest value in the diagnosis of sepsis compared with procalcitonin (PCT) and C‐reactive protein (CRP), which are also important biomarkers of infection. Traditional IL‐6 detection methods include chemiluminescence immunoassays (CLIA), enzyme‐linked immunosorbent assays (ELISA) and electrochemiluminescence immunoassays (ECLIA).
Medical Scientists at the Second Affiliated Hospital of University of South China (Hengyang, China) developed a quantum dot (QD)‐based fluorescence lateral flow immunoassay (LFIA) strip that can rapidly and accurately detect IL‐6 levels. The QD‐based LFIA strips were fabricated by conjugating cadmium selenide/zinc sulfide (CdSe/ZnS) QDs to the IL‐6 antibody. The strips were made of nitrocellulose (NC) membranes, semi‐rigid polyvinylchloride (PVC) sheets, and polyester fiber. The IL‐6 CLIA kits were from Beckman Coulter (Pasadena, CA, USA).
The fluorescence intensity of the test (T) line and the control (C) line on the strip were detected using the self‐designed KF‐Q001‐A fluorescence immunoassay analyzer (Kingfocus Biomedical Engineering Co., Ltd, Shenzhen City, China). The QDs and antibodies were dispensed onto the strip using a piece of three‐dimensional gold‐spraying equipment. IL‐6 CLIA detection was performed on the Beckman Coulter Dxl800 instrument. A total of 200 human serum samples were obtained from a local hospital, The IL‐6 concentrations of these samples ranged from 0 to 580.42 ng/mL. The samples were detected using the strip and the Beckman IL‐6 CLIA kit within two hours of each other.
The investigators reported that the test strip's linear range was 10–4,000 pg/mL, with a linear correlation coefficient of R2 ≥ 0.959. The sensitivity of the test strip was 1.995 pg/mL. The recovery rate was 95.72%–102.63%, indicating satisfying accuracy. The coefficient of variation (CV) of the intra‐assay was 2.148%–3.903%, while the inter‐assay was 2.412%–5.293%, verifying the strip's high precision. The cross‐reaction rates with various interleukins (IL‐1α, IL‐1β, IL‐2, IL‐4, and IL‐8) and interferon‐γ (IFN‐γ) were all less than 0.1%.
The authors concluded that they had successfully established a QD‐based LFIA method for rapid and accurate detection of human serum IL‐6, providing a more simple, robust, and economic point-of-care technology (POCT) for IL‐6 quantification, which is of great value for the early detection and treatment of sepsis and related disorders. The study was published on March 24, 2021 in the Journal of Clinical Laboratory Analysis.
Related Links:
Second Affiliated Hospital of University of South China
Beckman Coulter
Kingfocus Biomedical Engineering Co., Ltd
IL‐6 has shown the highest value in the diagnosis of sepsis compared with procalcitonin (PCT) and C‐reactive protein (CRP), which are also important biomarkers of infection. Traditional IL‐6 detection methods include chemiluminescence immunoassays (CLIA), enzyme‐linked immunosorbent assays (ELISA) and electrochemiluminescence immunoassays (ECLIA).
Medical Scientists at the Second Affiliated Hospital of University of South China (Hengyang, China) developed a quantum dot (QD)‐based fluorescence lateral flow immunoassay (LFIA) strip that can rapidly and accurately detect IL‐6 levels. The QD‐based LFIA strips were fabricated by conjugating cadmium selenide/zinc sulfide (CdSe/ZnS) QDs to the IL‐6 antibody. The strips were made of nitrocellulose (NC) membranes, semi‐rigid polyvinylchloride (PVC) sheets, and polyester fiber. The IL‐6 CLIA kits were from Beckman Coulter (Pasadena, CA, USA).
The fluorescence intensity of the test (T) line and the control (C) line on the strip were detected using the self‐designed KF‐Q001‐A fluorescence immunoassay analyzer (Kingfocus Biomedical Engineering Co., Ltd, Shenzhen City, China). The QDs and antibodies were dispensed onto the strip using a piece of three‐dimensional gold‐spraying equipment. IL‐6 CLIA detection was performed on the Beckman Coulter Dxl800 instrument. A total of 200 human serum samples were obtained from a local hospital, The IL‐6 concentrations of these samples ranged from 0 to 580.42 ng/mL. The samples were detected using the strip and the Beckman IL‐6 CLIA kit within two hours of each other.
The investigators reported that the test strip's linear range was 10–4,000 pg/mL, with a linear correlation coefficient of R2 ≥ 0.959. The sensitivity of the test strip was 1.995 pg/mL. The recovery rate was 95.72%–102.63%, indicating satisfying accuracy. The coefficient of variation (CV) of the intra‐assay was 2.148%–3.903%, while the inter‐assay was 2.412%–5.293%, verifying the strip's high precision. The cross‐reaction rates with various interleukins (IL‐1α, IL‐1β, IL‐2, IL‐4, and IL‐8) and interferon‐γ (IFN‐γ) were all less than 0.1%.
The authors concluded that they had successfully established a QD‐based LFIA method for rapid and accurate detection of human serum IL‐6, providing a more simple, robust, and economic point-of-care technology (POCT) for IL‐6 quantification, which is of great value for the early detection and treatment of sepsis and related disorders. The study was published on March 24, 2021 in the Journal of Clinical Laboratory Analysis.
Related Links:
Second Affiliated Hospital of University of South China
Beckman Coulter
Kingfocus Biomedical Engineering Co., Ltd
Latest Technology News
- Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer
- Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
- Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
- Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
- Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
- Smartphones Could Diagnose Diseases Using Infrared Scans
- Novel Sensor Technology to Enable Early Diagnoses of Metabolic and Cardiovascular Disorders
- 3D Printing Breakthrough Enables Large Scale Development of Tiny Microfluidic Devices
- POC Paper-Based Sensor Platform to Transform Cardiac Diagnostics
- Study Explores Impact of POC Testing on Future of Diagnostics
- Low-Cost, Fast Response Sensor Enables Early and Accurate Detection of Lung Cancer
- Nanotechnology For Cervical Cancer Diagnosis Could Replace Invasive Pap Smears
- Lab-On-Chip Platform to Expedite Cancer Diagnoses
- Biosensing Platform Simultaneously Detects Vitamin C and SARS-CoV-2
- New Lens Method Analyzes Tears for Early Disease Detection
- FET-Based Sensors Pave Way for Portable Diagnostic Devices Capable of Detecting Multiple Diseases
Channels
Clinical Chemistry
view channelMass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication
Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more
First Comprehensive Syphilis Test to Definitively Diagnose Active Infection In 10 Minutes
In the United States, syphilis cases have surged by nearly 80% from 2018 to 2023, with 209,253 cases recorded in the most recent year of data. Syphilis, which can be transmitted sexually or from mother... Read more
Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse
Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read moreMolecular Diagnostics
view channel
First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis
Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more
New Molecular Label to Help Develop Simpler and Faster Tuberculosis Tests
Tuberculosis (TB), the deadliest infectious disease globally, is responsible for infecting an estimated 10 million people each year and causing over 1 million deaths annually. While chest X-rays and molecular... Read more
Biomarker Discovery Paves Way for Blood Tests to Detect and Treat Osteoarthritis
The number of individuals affected by osteoarthritis is projected to exceed 1 billion by 2050. The primary risk factor for this common, often painful chronic joint condition is aging, and, like aging itself,... Read moreHematology
view channel
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read more
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read moreMicrobiology
view channel
Molecular Stool Test Shows Potential for Diagnosing TB in Adults with HIV
Tuberculosis (TB), caused by the bacterium Mycobacterium tuberculosis, led to 1.25 million deaths in 2023, with 13% of those occurring in people living with HIV. The current primary diagnostic method for... Read more
New Test Diagnoses Bacterial Meningitis Quickly and Accurately
Bacterial meningitis is a potentially fatal condition, with one in six patients dying and half of the survivors experiencing lasting symptoms. Therefore, rapid diagnosis and treatment are critical.... Read morePathology
view channel
Groundbreaking Chest Pain Triage Algorithm to Transform Cardiac Care
Cardiovascular disease is responsible for a third of all deaths worldwide, and chest pain is the second most common reason for emergency department (ED) visits. With EDs often being some of the busiest... Read more
AI-Based Liquid Biopsy Approach to Revolutionize Brain Cancer Detection
Detecting brain cancers remains extremely challenging, with many patients only receiving a diagnosis at later stages after symptoms like headaches, seizures, or cognitive issues appear. Late-stage diagnoses... Read moreTechnology
view channel
Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer
Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more